In addition to two independent reports demonstrating significant “outlier” responses of uveal melanoma to pembrolizumab in the setting of germline MBD4 mutations, the direct mechanism of pathogenesis also has begun to be uncovered.203, 204, 205. This evidence concerns the gene MBD4 and uveal melanoma.